NCCN Guidelines for Patients® | Lung Cancer - Non-Small Cell Lung Cancer

49 NCCN Guidelines for Patients ® : Lung Cancer – Non-Small Cell, 2018 low blood cell counts, not feeling hungry, nausea, vomiting, diarrhea, hair loss, and mouth sores. Lung damage may also occur at the time of treatment. Most side effects appear shortly after treatment starts and will stop after treatment. However, other side effects are long-term or may appear years later. Late side effects include another type of cancer, heart disease, low levels of thyroid hormones (hypothyroidism), and problems having babies (infertility). Not all side effects of chemotherapy are listed here. Please ask your treatment team for a complete list of common and rare side effects. If a side effect bothers you, tell your treatment team. There may be ways to help you feel better. There are also ways to prevent some side effects. Targeted therapy Targeted therapy is a class of drugs. It works by stopping key molecules that help cancer cells grow. It is less likely to harm normal cells than chemotherapy. Targeted therapies for lung cancer are listed in Guide 6 . These treatments are briefly described next. Some side effects are listed. Ask your treatment team for a full list of common and rare side effects. In Part 7, 5 Overview of cancer treatments Targeted therapy Guide 6. Targeted therapy Generic (chemical) name Brand name (sold as) Target molecule(s) Ado-trastuzumab Kadcyla ® HER2 Afatinib Gilotrif ® EGFR and HER2 Alectinib Alecensa ® ALK Bevacizumab Avastin ® VEGF Brigatinib Alunbrig™ ALK Ceritinib Zykadia ® ALK Cetuximab Erbitux ® EGFR Crizotinib Xalkori ® ALK, ROS1, and MET Dabrafenib Tafinlar ® BRAF V600E Erlotinib hydrochloride Tarceva ® EGFR Gefitinib Iressa ® EGFR Osimertinib Tagrisso™ EGFR Ramucirumab Cyramza ® VEGF Trametinib Mekinist ® MEK1 and MEK2 (for BRAF mutation) Vandetanib Caprelsa ® RET Vemurafenib Zelboraf ® BRAF V600E